Last reviewed · How we verify
AZD2389
AZD2389 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.
AZD2389 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes. Used for Moderate to severe atopic dermatitis.
At a glance
| Generic name | AZD2389 |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | PI3K delta and PI3K gamma inhibitor |
| Target | PI3K delta and PI3K gamma |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting these enzymes, AZD2389 is thought to modulate immune cell function and potentially treat various inflammatory and autoimmune diseases. However, the exact mechanism of action is still being researched and refined.
Approved indications
- Moderate to severe atopic dermatitis
Common side effects
- Nasopharyngitis
- Upper respiratory tract infection
- Headache
- Musculoskeletal pain
- Diarrhea
Key clinical trials
- The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis. (PHASE1)
- A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389 (PHASE1)
- A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy Participants (PHASE1)
- A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis. (PHASE2)
- A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine (PHASE1)
- A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants (PHASE1)
- A Study to Investigate the Pharmacokinetics of AZD2389 When Administered Alone and in Combination With Itraconazole in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD2389 CI brief — competitive landscape report
- AZD2389 updates RSS · CI watch RSS
- AstraZeneca portfolio CI